VERA · Vera Therapeutics, Inc.
$36.06
-1.12 (-3.00%)
At close · Jul 22
Market Cap
$2.59B
Shares
71.78M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$36.06
Open$36.85
Day$36.04–37.44
52W$19.07–56.05
Avg vol 30d2.1M
Short int13.5M · 18.8% float · 5.9d
Short vol69%
Last earningsNov 5, 2025
DataMay 2021–Jul 2026
Filing10-Q · May 7
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 7, 2026
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 18.7 · elevated
Equity put/call 0.61
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−7%
below
Price vs 50-day avg
−3%
below
RSI (14)
39
neutral
MACD trend
Negative
52-week position
46%
mid-range
Momentum
relative strength
1-month return
−6%
trailing
6-month return
−20%
trailing
YTD return
−29%
this year
Relative strength
−28%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $37 › 200d $39 — 200d above 50d
Institutional flow
Accumulating
23 of 230 funds reported for Jun 30 · net +64.4K sh shares · +3 new
Insider flow
Distributing
Net -$679.7K over 90 days · 100% sells
Short interest
Rising
18.84% of float · ▲ +14.2% MoM · 5.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
230 holders — near 3-yr high, broad support
Squeeze score
72
high risk · 0–100
Fundamentals
EPS growth
−69%
Y/Y
Free cash flow
$-241.7M
Balance sheet
$279.9M
net cash
Quant / Vol
risk profile
Volatility
59%
annualized · 1-yr
Max drawdown
−44%
past year
ATR
6.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−7%
Bearish
Price vs 50-day avg
−3%
Neutral
RSI (14)
39
Neutral
MACD trend
Negative
Bearish
52-week position
46%
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $37 › 200d $39 — 200d above 50d
Institutional flow
Accumulating
23 of 230 funds reported for Jun 30 · net +64.4K sh shares · +3 new
Insider flow
Distributing
Net -$679.7K over 90 days · 100% sells
Short interest
Rising
18.84% of float · ▲ +14.2% MoM · 5.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
230 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $19
Now $36 · 46%
52-wk high $56
vs 200-day avg -7%
vs 50-day avg -3%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
VERA
this stock
Vera Therapeutics, Inc.
|
$2.59B | -28.8% | — | — | 18.8% |
|
ONC
BeOne Medicines Ltd.
|
$462.38B | +5.3% | +22179.2% | 941.0 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$119.94B | +4.2% | +46.2% | 28.1 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$68.27B | -15.5% | +20.8% | 15.9 | 3.3% |
|
ARGX
Argenx SE
|
$57.84B | +9.9% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| VERA | -15.2% | -5.6% | -20.1% | -16.0% | -28.8% |
| SPY | -1.0% | +1.9% | +7.5% | +0.1% | +9.6% |
| vs SPY | -14.2% | -7.5% | -27.6% | -16.1% | -38.4% |
Key facts
CIK
1831828
CUSIP
92337R101
13F (30d)
20 filings
20 filers
Visit website
Investor relations